The treatment of multiple sclerosis (MS) has evolved remarkably over the past 25 years. This progress has been enabled by advances in research, drug development and active engagement of the scientific community with regulatory authorities. However, an inconsistent approach to MS disease courses could have a negative impact on the drug development process.
A.J.T. acknowledges support from the UCL/UCLH National Institute of Health (NIHR) Biomedical Research Centre (BRC).